Acquired von Willebrand syndrome (AvWS) has been reported in eight children with Wilms tumor (nephroblastoma in four boys and four girls) at a mean age of 3.3 years (range, 0.33-9 years). Only three of eight patients with AvWS in Wilms tumor presented with mild mucocutaneous bleeding symptoms. The AVWS in seven children with Wilms tumor featured either undetectable or very low von Willebrand factor antigen (vWF.Ag) levels (mean, 3%) and decreased values for vWF ristoectin cofactor (RCF) activity (mean, 20%) and factor VIII coagulant (VIIIc) activity (mean, 16%). The response to 1-desamino-8-argi nine vasopressin (DDAVP) was good in two and poor in one patient. Multimeric analysis of the vWF showed a normal pattern of type I von Willebrand disease (vWD) in three patients and an absence of multimers consistent with type In v WD in two patients. The higher functional levels, as compared with antigen levels, with increased ratios for factor VIIIc/vWFAg (mean, 5.3) and vWF.RCF/vWF.Ag (mean, 6.6) in seven patients with Wilms tumor are unexplained physiologically and are not consistent with type I vWF deficiency. The absence of vWD in the patient's family, and the return of factor VIII-VWF parameters to normal after chemotherapy or surgical removal of the Wilms tumor, support the diagnosis of AvWS causally related to the Wilms tumor. The causative agent is thought to be hyaluronic acid secreted by nephroblastoma cells of the Wilms tumor. Prospective studies to determine the nature of AvWS in children with Wilms tumor are warranted. Key Words: Acquired von Willebrand syndrome&mdash; factor VIII-Hyaluronic acid&mdash;von Willebrand disease&mdash;von Willebrand factor&mdash;Wilms tumor. The acquired von Willebrand syndromes (AVWS) closely parallel the subtypes of congenital von Willebrand disease (vWD) (1). In type I ~V~~, factor VIII coagulant (Vlllc) activity, von Willebrand factor antigen (vWF.Ag), and vWF ristocetin cofactor activity (vWF.RCF) are equally decreased. In vWD type I, the ratio of vWF.RCF/Ag, the multimeric pattern of vWF and the response to l-desammo-8-D-arginmc vasopressin (DDAVP) are normal (1). von Willebrand disease type IIA is a functional deficiency of the vWF, with a decreased vWF.RCF/Ag ratio. In vWD type HA, the high vWF multimers are absent, and the response to DDAVP is abnormal. Type III vWD features very low or unde-/ tectable factor VIII-VWF levels, and either no or poor response to DDAVP. Acquired von Willebrand syndrome has been described in association with monoclonal gammopathies, lymphoid, myeloproliferative, autoimmune and metabolic or hormonal disorders, tumors, infection, or the use of medical drugs (2-5). The type, natural history, severity, and outcome of treatment in patients with. AvWS depend largely on the mechanism and severity of the vWF deficiency, either associated with or caused by the nature of the underlying disorder. In this study, we report on a detailed critical analysis of the bleeding ' manifestations, laboratory features, type, and pathophysiology of AVWS associated with Wilms tumor. This article also focuses on the response to DDAVP, me clinical efficacy of factor VIII concentrate, and the outcome after chemotherapy and surgical removal of the Wilms tumor.
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Laboratory findings
Routine bleeding time was prolonged in six patients and normal in two patients. The platelet counts were normal in all except one (case ~~. ' Ristc~c~tiu-indu~~d platelet aggregation (RIPA) was decreased in one patient with severe 'v~F.A~ deficiency and not tested in the other seven patients. Activated partial thromboplastin time was prolonged in seven patients in whom the factor VIII coagulant (Vlllc) levels were between 5 and 2'~'~1~. Activated partial thromboplastin time was normal one patient who had a factor VIIIc level of 37%. The values for factor were between 5 and 37% with a mean of 17.5% ( Table 1 ).
The AvWS in seven children with Wilms tumor featured very low vWF.Ag levels between less than 1% and 6% (mean, 3%) and a normal v~VF:A~ level in one patient (case 8). The values for vWF.RCF were significantly higher between 5 and 54%; mean, 25% (Table ' l~. Multimeric analysis of the VWF revealed a normal pattem consistent with type I vWD in three cases and the virtual absence of multimers consistent with type III ' vWD in two cases (Table l ~.
The diagnosis of AVWS in case 8 is questionable because the values for VWF.Ag, VWF.RCF, and factor Vlllc were normal, borderline, and moderately decreased, respectively ( Table 1 ). The much higher functional levels, as compared with antigen levels, with a mean factor Vlllc/vWFAg ratio of 5.8 and a mean vWF.RCF/Ag ratio of 8.3 in the reported cases of Wilms tumor (Table l ) The results of mixing experiments by incubating patient plasma and normal plasma failed to show any inhibition of factor ~I~I~, vVG'F.A~, and vWF.RCF in five evaluated patients (Table I ) . ' The AvWS in case 3, of a patient had uncontrollable epistaxis, was associated with hyperviscosity caused by elevated semm hyaluronic acid, very probably secreted by nephroblastoma cells of th~. Wilms tumor (9, 12) . Repeated coagulation tests in case 3 showed undetectable factor VIII-VWF related antigen levels in the Laurel] rocket immunoelectrophoretic assay and normal values for factor Vlllc and von Willebrand factor activity, consistent with spurious vWF.Ag deficiency (Table  1 ). Mixing studies using varying proportions of hyaluronic acid and normal pooled plasma to assess the inhibitory effect of hyaluronic acid on the factor VIII/VWF ' complex showed an 80 to 90% inhibition of factor V!Hc activity and a complete inhibition of factor VIII/vWf antigen to undetectable levels in the Laurel rocket immunoelectrophoresis (9) . These in vitro data may explain the ex vivo findings of both undetectable or very low vV'~F:,~~&dquo; and the much less pronounced functional deficiency of factor Vlllc and VWF.RCF, which result in an inversed and abnormally increased v~VF.I~CFlA~ ratio. The same inversed and abnorrnally increased VWF.RCF/ Ag ratio of 2~. t :~ = 6.7 could be demonstrated in seven cases, which is consistent with a very atypical variant of AvWS in Wilms tumor (cases 1-7, Table 1 ).
Results of indirect immunofluorescence of Wilms tu-
mor specimens in two patients (cases 2 and 4) using monospecific rabbit anti-VIII related antigen showed no absorption of factor VIII-VWF on the nephroblastoma cells, but normal expression of factor VIII-VWF in vessel wall endothelial cells (8, 10) .
Management and outcome of treatment
Infusion of 12 units of cryoprecipitate in case 6, of a patient with type III AvWS, resulted in a significant increase of factor VIIIc and a poor recovery of VWF.RCF, which was followed by no abnormal bleeding either dur-ing or after open renal biopsy (Table 2 ) ( l ~ ~: Five days later, the coagulation parameters were more consistent with type I AvWS, and the response to DDAVP was good, with a three to fourfold increase of factor VIIIc and vWF.RCF. respectively, whereas the vWF.Ag could not be measured because of heavy background staining in the Laurel] rocket immunoelectrophoresis, consistent with spurious v~NF:~g deficiency ( Table 2 ). The response to DDAVP was very good in case 8, of a patient with borderline AvWS type I ( Table 2) (11) .
Chemotherapy in five 'children with Wilms tumor (cases 3, 5-8) was successful in reducing the tumor burden, which was accompanied by the disappearance of the AVWS (9,1 I ). Subsequent surgical resection of the residual tumor mass by nephrectomy without the need of I factor VIII-wWF substitution was uneventful. ! Surgery as the primary treatment modality under the / cover of routine substitution therapy, including cryoprecipitate or factor VIII-vWF concentrate, was uneventful in cases and 4 (7,'I(?)~ Despite having received fresh frozen plasma (FFP) and cryoprecipitate before surgery, one patient (case 2) developed serious bleeding and re-! quired additional therapy, in~lu~in~, factor VIII concentrate, FFP, platelet, and whole blood (estimated blood loss, 3600 mL) (8) . Surgical removal of the Wilms tumor in three children (cases !, 2 and 4) was fatlawed ~y the I recovery of factor Vlllc, ~'V~IF.Ag; and vWF.RCF levels to completely normal levels (Table 1) ~6--~; I f~). ! DISCUSSION Laboratory findings in seven cases of AVWS in Wiltns tumor showed a very peculiar picture that featured either undetectable or very low vWF' antigen (< 6%) levels and various degrees of functional factor Vlllc (mean, 1 ~°~~; ' range, 5-37%) and vWF.RCF (mean, 2O~o; range, 5-46%) deficiency (6) (7) (8) (9) (10) (11) . Multimeric analysis of the von Willebrand factor in five patients (cases 4-8) showed a pattern consistent with AvW s type I in three ' patients and type III in two patients, indicating the presence of normal vWF and the absence of vWF, respec- lively ( 0, l I ~. None of these latter five patients with type lot III AvWS had spontaneous bleeding symptoms at time of presentation of the Wilms tumor, despite severe factor VIII and vWF deficiency in at least three of these patients ( Table 1) . The undetectable or very low levels of factor VIII RAg ~nd ~t~YF and the much less and variable degrees of d~Ilcient I'unct~c~n~l FVIII~ and vWF activities associated with Wilms tumor, reflect a very atypical variant of AVWS, which is not compatible with type I, II, or III VWF deficiency ( (12) . Either some other nonimmunologic mechanism, or a plasma factor secreted by nephroblastoma cells of the Wilms tumor, may be responsible for the FVIII-VWF deficiency. A possible mechanism involved in the cause and pathophysiology of atypical AvWS in Wilms tumors may bẽ~y alurani~ acid secreted by nephroblastoma cells (9, 13) . The in vitro studies of Bracey et al. (9) have shown an interaction between hyaluronic acid and the factor VIII/ VWF complex, which may result in a very atypical variant of AvWS that features undetectable vWF.Ag in the immunoelectrophoretic assay and various degrees of deficiency in factor VIlIc and VWF activity, with increased ratios for both factor VIII.c/Ag and ~rWF:R~FIAg; The data of Bracey et al. (9) are consistent with a model in which a plasma factor (either hyaluronic acid or another factor) secreted by the Wilms tumor interacts with vWF and results in the atypical variant of AvWS (11) . This model does not exclude additional hemostatic abnormalities that contribute to an increased bl ing tendency. Hyaluronic acid secreted by nephroblastoma cell may interfere with platelet function or cause hyperviscosity (9, 13) .
The presented review demonstrates that the data are too poor to clearly define the characteristics and patho-physiology of the acquired vWF deficiency in each of the reports on AvWS in Wilms tumor (6) (7) (8) (9) (10) (11) . Prospective studies to the true incidence and nature of AvWS in children presenting with an abdominal mass suspected for Wilms tumor are warranted. such a study, the coagulation screen should include bleeding time, platelet function, prothrombin time, APTT, factor Vlllc, vWF.Ag, VWF.RCF, vWF collagen binding assay, and ristocetin-induced platelet aggregation. When indicated, a diagnostic work-up for the diagnosis of AvWS should follow the recent recommendations (5, 14, 15) , including vWF multimeric analysis, antifactor VIII-VWF activities, a DDAVP challenge test, platelet vWF, parameters, and determination of serum hyaluronic acid, and, in case of applicability, the elucidation of the interaction between hyaluronic acid and factor VIII/VWF complex both before and after appropriate treatment of the Wilms tumor (9, 11) .
